Oncology Clinical Trial Experts For Complex Trial Design
Complex oncology trials require deep science, regulatory expertise, and coordination. See how integrated teams and adaptive designs speed startup, protect patients, and scale.
As a global oncology CRO, Ergomed delivers customized clinical trial solutions for oncology drug development—from first-in-human (FIH) studies to post-marketing. With deep expertise in oncology consulting, rare disease clinical trials, adaptive trial designs, immuno-oncology, and cell and gene therapy (ATMPs), we’ve successfully delivered more than 500 oncology studies, enrolling 30,000+ patients across 3,800+ sites worldwide.
Proven Expertise in Oncology Clinical Trials
Oncology trials require an oncology CRO with a robust scientific team, deep regulatory knowledge, compassionate understanding of, and dedication to improving the patient experience, as well as the expertise to support clinical sites and investigators in recruiting patients and ensuring their safety.
At Ergomed, our multidisciplinary teams of oncology trial experts include regulatory specialists, clinical strategists, site support managers, and data scientists. We bring a deep understanding of personalized medicine, solid tumor and hematologic malignancies, and rare oncology indications.
- 500+ oncology studies
- 30,000+oncology patients
- 3,800+ global sites
End-to-End Collaboration for Complex Oncology Trials
Efficient execution of complex oncology clinical trials requires seamless collaboration between sponsors, clinical sites, and an experienced oncology CRO. As a global clinical research organization, Ergomed provides integrated clinical research support that ensures every oncology program is delivered with precision and speed.
Our oncology project managers — each averaging 15+ years of trial experience — bring hands-on expertise in adaptive, umbrella and basket trial designs. Through dedicated oncology consulting and specialized early-phase oncology CRO services, we guide sponsors from protocol development through regulatory submission and global execution.
Ergomed’s integrated trial model delivers faster startup, real-time data access, accurate monitoring of dose-limiting toxicities, and patient-first safety protocols. We specialize in early-phase oncology clinical trials, where agility, rapid response, and cross-functional communication are critical to success.
Transforming First-in-Human Oncology Trials: A Strategic Guide
Download our guide for designing early oncology studies. Learn how Ergomed’s expertise as a global oncology CRO helps sponsors optimize dose-escalation strategies, ensure patient safety, and meet regulatory requirements.
Market Approval for a Novel Non-Hodgkin Lymphoma (NHL) Therapy
In a global head and neck cancer study, Ergomed achieved a 560% enrollment increase within three months by leveraging its clinical research support network and replacing underperforming sites.
Beyond Oncology: Rare and Complex Indications
Ergomed delivers specialized expertise in ultra-rare and complex cancer trials.
From rare indications such as sarcoma and neuroblastoma to complex indications like head and neck, pancreatic, and liver, we apply scientific rigor and a patient-first approach.
Oncology Site Management and Patient Access
Ergomed’s site management model is optimized for patient-centric oncology trials.
Our team delivers full operational support—from site startup and patient recruitment to protocol compliance and data integrity—ensuring trials run smoothly across multiple geographies. Our approach is grounded in a proven patient-first site management model, part of Ergomed CARE™, focused on supporting patients and investigators & sites throughout the clinical journey. We streamline site identification and startup through robust site feasibility services to accelerate your oncology trial timelines.
Collaborating for Accelerated Oncology Trials and Enhanced Patient Access
- NEXT Oncology Partnership
Focuses on Phase I trials with locations in San Antonio, Virginia, and beyond, providing patients access to cutting-edge therapies in immune-oncology and targeted treatments.
- The START Center Partnership
Specializes in Phase I & II oncology clinical trials across multiple U.S. and international locations, focusing on translational medicine and novel cancer therapies.
Oncology CRO with a Track Record of Success
Ergomed is a proven global oncology CRO and trusted clinical research organization, partnering with sponsors across early-phase, pivotal, and post-marketing oncology trials.
Our reputation as a flexible, reliable, and scientifically driven clinical trial CRO is built on decades of experience, operational performance, and strong sponsor partnerships. From rare tumors to large-scale immuno-oncology clinical trials, Ergomed combines deep expertise with strategic patient recruitment and global clinical research support. Our ability to deliver trials on time and on target has established us as a preferred partner for biotech and pharmaceutical companies worldwide.